Login to Your Account

Clinic Roundup

Tuesday, February 15, 2011
Oxigene Inc., of South San Francisco, entered a cooperative research and development agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program to collaborate on a randomized Phase II study of Zybrestat (fosbretabulin) in combination with Avastin (bevacizumab, Genentech Inc./Roche AG) in patients with relapsed ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription